[Long term results of vaccination against viral hepatitis B using recombinant vaccine Engerix B]. / Odlegle wyniki szczepienia przeciwko wirusowemu zapaleniu watroby typu B przy uzyciu rekombinowanej szczepionki Engerix B.
Przegl Epidemiol
; 46(4): 271-9, 1992.
Article
em Pl
| MEDLINE
| ID: mdl-1305775
ABSTRACT
Among nineteen persons vaccinated against hepatitis B (recombinant Engerix B vaccine) fifteen (80 per cent) have developed anti-HBs (investigated 30 days after the third doses) on the protective level (10 U/l). After three and a half year three of them lost antibodies, and four had anti-HBs at level below 100 U/l. All of them received a booster doses, which resulted in a very high anti-HBs level one month later. Four persons without anti-HBs after the basic vaccination received in turn two booster doses at the 3rd and 46th month. Only one person of them have remained a non-responder. We suggest to control a level of anti-HBs one month after basic vaccination for individual determination of the term of booster dose.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Vacinas Sintéticas
/
Vacinas contra Hepatite B
/
Hepatite B
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
Pl
Ano de publicação:
1992
Tipo de documento:
Article